Hybridoma: A Journal of Molecular Immunology and Experimental and Clinical Immunotherapy

Hybridoma: A Journal of Molecular Immunology and Experimental and Clinical Immunotherapy Published by Mary Ann Liebert Inc. www.liebertpub.com/hyb The essential resource for scientists and clinicians in the fields of molecular immunology and immunopathology, and for all those applying molecular immunological methods for experimental and therapeutic purposes.
Audience	Scientists and clinicians
Frequency	6 issues a year: February, April, June, August, October, December
Editorial Focus	Presents the latest developments in characterization and production of monoclonal antibodies. Coverage includes: Isolation and production methods Characterization, epitope mapping Delivery systems for immunotherapeutic and experimental purposes Application of mAbs to elucidate signaling pathways Development of immunotherapeutic compounds Generation of probes for molecular monitoring Creation of diagnostic reagents, experimental and clinical Analysis of mAb antagonistic/inhibitory effects Cellular and molecular responses to mAb immunization Immunoscreening for identification of molecular variants and markers New sources for availability of fully characterized mAbs
Editor(s) in Chief	Zenon Steplewski Department of Cancer Biology, Thomas Jefferson University, Jefferson Medical College, Philadelphia
Print Advertising Options	Adverts, Inserts & Supplements
Digital Advertising Options	Banners on website Banners on subscriber Table of Contents email alerts
Further Information	Heleen Vodégel Tel: +44 (0) 1875 825 700 hvodegel@impressmedia.com
Publisher	Hybridoma is owned and published by Mary Ann Liebert, Inc. Editorial headquarters: 140 Huguenot Street, New Rochelle, New York 10801, USA. Phone: +1 (914) 740-2100. Fax: +1 (914) 740-2101 www.liebertpub.com